Astrocytes are the gatekeepers of neuronal energy supply. In neurodegenerative diseases, bioenergetics demand increases and becomes reliant upon fatty acid oxidation as a source of energy. Defective fatty acid oxidation and mitochondrial dysfunctions correlate with hippocampal neurodegeneration and memory deficits in Alzheimer's disease (AD), but it is unclear whether energy metabolism can be targeted to prevent or treat the disease. Here we show for the first time an impairment in fatty acid oxidation in human astrocytes derived from induced pluripotent stem cells of AD patients. The impairment was corrected by treatment with a synthetic peroxisome proliferator activated receptor delta (PPARβ/δ) agonist GW0742 which acts to regulate an array of genes governing cellular metabolism. GW0742 enhanced the expression of CPT1a, the gene encoding for a rate-limiting enzyme of fatty acid oxidation. Similarly, treatment of a mouse model of AD, the APP/PS1-mice, with GW0742 increased the expression of Cpt1a and concomitantly reversed memory deficits in a fear conditioning test. Although the GW0742-treated mice did not show altered astrocytic glial fibrillary acidic proteinimmunoreactivity or reduction in amyloid beta (Aβ) load, GW0742 treatment increased hippocampal neurogenesis and enhanced neuronal differentiation of neuronal progenitor cells. Furthermore, GW0742 prevented Aβ-induced impairment of long-term potentiation in hippocampal slices. Collectively, these data suggest that PPARβ/δ-agonism alleviates AD related deficits through increasing fatty acid oxidation in astrocytes and improves cognition in a transgenic mouse model of AD.
Alzheimer's disease (AD) is the most common cause of dementia in the elderly (Grimm, Mett, Grimm, & Hartmann, 2017) . In AD, as in many other neurodegenerative diseases, normal astrocytic processes are compromised, leading to altered neuronal functions and memory deficits (Acosta, Anderson, & Anderson, 2017) . Whereas the majority of AD cases are late-onset (LOAD) without evidence of genetic inheritance, 1-6% of the cases manifest at an early age (early-onset, EOAD) and are caused by mutations in genes, such as presenilin-1 (PSEN1), responsible for the accumulation of toxic amyloid beta (Aβ) in the brain, representing the main pathological hallmark of AD (Grimm, Rothhaar, & Hartmann, 2012) . PSEN1 is a catalytic subunit of the γ-secretase complex that participates in the amyloidogenic cleavage of amyloid precursor protein (APP) releasing the 1-42 fragment of Aβ in the extracellular space where it further aggregates and deposits as senile Aβ plaques (Grimm et al., 2012) . APP cleavage products play an essential role in regulating lipid homeostasis, and vice versa, FA metabolism is intertwined with APP processing and Aβ generation (Grimm et al., 2017) .
Defects in metabolism correlate with the progression of AD. Glycolysis is impaired (Bigl, Apelt, Eschrich, & Schliebs, 2003) , but also the metabolic products of FAO are reduced in the brains of AD patients (Ciavardelli et al., 2016) . Furthermore, inhibition of FAO increases oxidative stress and induces the accumulation of Aβ in vitro and in vivo (Shi et al., 2016) . Administration of substrates for FAO rescues Aβ-induced memory impairment by facilitating astrocytic oxidative metabolism (Gibbs, Gibbs, & Hertz, 2009) . Similarly, facilitation of FAO has been linked to memory improvement (Gibbs et al., 2009 ) and an increase in neurogenesis (Stoll et al., 2015) . Metabolism of FAs and Aβ is influenced by peroxisome proliferator receptor beta/delta (PPARβ/δ) target genes which regulate the lipid transport and processing in other cell types (Silva-Veiga et al., 2018) . Therefore, activation of PPARβ/δ may emerge as a relevant approach to manage also brain metabolism, especially through astrocytic functions, since astrocytes are the major site for FAO in the brain.
Here, we show for the first time that human astrocytes, differentiated from induced pluripotent stem cells (iPSCs) of AD patients with an amyloidogenic mutation in delta 9 exon of PSEN1 (PSEN1ΔE9), show impaired FAO capacity. The impairment is corrected by treatment with GW0742, a synthetic ligand agonist of PPARβ/δ, which subsequently increases astrocytic expression of CPT1A. Similarly, treatment of APPswe/PSEN1dE9 (APP/PS1) mice with GW0742 increases the expression of Cpt1a, concomitantly reverses memory deficits in fear conditioning test and reduces the expression of proinflammatory mediators. This study is the first to address the ADrelated defect in FAO, specifically in astrocytes, and suggests that astrocytic lipid metabolism provides a potential target for AD therapy. The iPSC-lines used in this study were generated from three healthy volunteers and from three EOAD patients carrying a deletion in the exon 9 of the PSEN1 gene (4.6 kb mutation; the Finnish PSEN1ΔE9) (Crook et al., 1998; Oksanen et al., 2017) . Two patients were diagnosed with AD and one was pre-symptomatic with no clinical diagnosis at the time of sample collection. To examine the correlation between ΔE9 mutation and AD phenotype, we also used corrected isogenic control lines created by CRISPR/Cas9 system from the pre-symptomatic and one symptomatic patients (Oksanen et al., 2017) . In addition, we used commercial embryonic stem cell line H9 (NIH approved WA09, WiCell, Madison, WI) . The absence of the most common genetic determinant of LOAD, namely APOE ε4 allele, was confirmed, and all cell lines carried neutral APOE ε3/ε3 alleles. All used iPSC lines had undergone detailed karyotype and phenotype evaluations described in Oksanen et al. (2017) , and expressed high levels of pluripotent markers, formed embryoid bodies, had the ability to form all three germ layers and presented normal euploid karyotypes (Oksanen et al., 2017) . The genders, phenotype, and origin of each line used in this study are presented in Table 1 .
| MATERIALS AND METHODS

| Human iPSC lines
Skin
| IPSC-derived astrocyte cultures
Generation of iPSCs and their differentiation to astrocytes was carried out as described earlier (Oksanen et al., 2017) . Briefly, somatic cells were reprogrammed into iPSCs using CytoTune™ -iPS 1.0 or CytoTune™ -iPS 2.0 Sendai Reprogramming Kits (Invitrogen, Eugene, OR). The resulting iPSCs were grown in Essential 8 Medium (E8; Life Technologies) on Matrigel-coated (Corning, NY) dishes and maintained by passaging with 0.5 mM ethylenediaminetetraacetic acid (EDTA) and keeping additional 5 μM Y-27632 ROCK-inhibitor (Selleckchem, Munich, Germany) in medium for 24 hr after passaging.
Astrocytic differentiation was initiated by changing the medium into neural differentiation medium (NDM) consisting of DMEM/F12
and Neurobasal (1:1), 1% B27 w/o vitamin A, 0.5% N 2 , 1% Glutamax, and 0.5% penicillin/streptomycin (P/S, 50 IU/50 μg/ml) (all from Invitrogen), 10 μM SB431542 (Sigma-Aldrich Co., St. Louis, MO) and 200 nM LDN193189 (Selleckchem). The resulting rosettes were expanded in NDM supplemented with 20 ng/ml basic fibroblastic growth factor (bFGF, Peprotech, Rocky Hill, NJ) for 2-3 days and then mechanically lifted onto ultra-low attachment plates (Corning). The resulting spheres were grown in astrocyte differentiation medium (DMEM/F12, 1% N 2 , 1% Glutamax, 1% nonessential amino acids, 0.5% P/S (50 IU/50 μg/ml) and 0.5 IU/ml heparin (Leo Pharma, Ballerup, Denmark), 10 ng/ml bFGF, and 10 ng/ml epidermal growth factor (EGF, Peprotech). Medium was changed every 2-3 days and the spheres maintained in astrocytic differentiation medium (ADM) for 6-8 months allowing the formation of pure astrocytic cultures. For experiments, spheres between 180 and 240 days in vitro (DIV) were dissociated with Accutase (Stem Cell Technologies, Cambridge, United Kingdom) to single cells and plated on Matrigel (BD Matrigel matrix, growth factor reduced; BD Biosciences, San Jose, CA) coated well plates or on Seahorse microplates (Seahorse Bioscience, North Billerica, MA) in ADM supplemented with 10 ng/ml ciliary neurotrophic factor and 10 ng/ml bone morphogenetic protein 4 (both from Peprotech).
| Adult mouse astrocyte cultures
Adult astrocytes were isolated as previously published (Iram et al., 2016 ) from 4.5-, 9-, and 20-month-old APP/PS1 mice. Briefly, mice were sacrificed by overdose with tribromoethanol (Avertin, SigmaAldrich) and transcardially perfused with ice-cold heparinized saline.
The brains excluding cerebellum and brain stem were dissected out and minced in Hank's balanced salt solution (HBSS) followed by dissociation into single cell suspension using the Neural dissociation kit (Miltenyi Biotech) according to manufacturer's instructions. After washing with phosphate-buffered saline (PBS), the cells were suspended into culture medium containing DMEM/F-12, 1× Glutamax, 10% iFBS, and 1% P/S, and plated on Poly-D-Lysine coated 6-well plates. The medium was changed every day for the first 7 days. The cells were detached with 0.25% Trypsin-EDTA and split every 7 days to expand the cell amount and used for experiments on 21-27 DIV.
| FA oxidation measurement
The oxidation of endogenous FAs was measured with the Seahorse XF24 analyzer and FA oxidation assay according to the manufacturer's instructions (Seahorse Bioscience). Cells were seeded at high density (100,000-125,000 per well) and cultured on Matrigel-coated XF24 cell culture microplate (Seahorse Bioscience) and were primed to utilize endogenous FAs as an energy source by replacing the maturation medium with substrate limited medium 24 hr before the measurement. Limited medium for adult mouse astrocytes consisted of DMEM/F12 without glucose (Biowest, Nuaillé, France), 0.5% Glutamax, 0.5% P/S (50 IU/50 μg/ml), supplemented with 2.5 mM glucose (Sigma-Aldrich), and 0.5 mM acyl-carnitine (Sigma-Aldrich). For iPSCastrocytes, limited medium contained also additional 0.5% N 2 and 0.5% nonessential amino acids. Limited medium was supplemented either with vehicle (dimethyl sulfoxide [DMSO]) or 1 μM or 10 μM
GW0742.
On the day of the assay, limited medium was replaced with FAO assay medium (Seahorse Bioscience) containing MgSO 4 0.8 mM, CaCl 2 1.8 mM, NaCl 143 mM, KCl 5.4 mM, NaH 2 PO 4 0.91 mM, L-AlaGln (GlutaMAX) 2 mM, supplemented with additional glucose 1 mM, acyl-carnitine 0.5 mM, and HEPES 5.0 mM, and adjusted to pH 7.4.
The plate was transferred to non-CO 2 incubator at +37 C 1 hr before the assay. A CPT1A inhibitor, etomoxir (Sigma-Aldrich), was added to half of the wells in the final concentration of 40 μM 15 min prior to starting the assay to allow it to be taken up by the cells and to bind to CPT1A. Assay test compounds, oligomycin, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and rotenone/antimycin A (all from Sigma-Aldrich) were added sequentially through automated injection during the assay at 1 μM final concentrations each, and measurements were repeated three times every 10 min. 
| Cytometric bead arrays
Cytokine concentrations were detected with the cytometric bead array (CBA) multiplex flex sets (BD Biosciences). Human Soluble Protein flex sets were used for detecting CCL5/RANTES, granulocytemacrophage colony-stimulating factor (GM-CSF), monocyte chemoat- 
| Animals and drug administration
| Contextual fear conditioning
We chose to examine memory functions of APP/PS1-mice with the hippocampus-dependent memory test 1 day after contextual fear conditioning as described before ( Hippocampus-dependent contextual fear memory formation was evaluated by scoring freezing behavior for 5 min when the mice were placed back into the same conditioning chamber 24 hr after training.
| Open field (OF) test
The mice 
| Immunohistochemistry
At the end of the behavioral testing, the mice were terminally anesthetized using tribromoethanol (Avertin, Sigma-Aldrich) and perfused transcardially with 0.01 M PBS, pH 7.4. After perfusion, the brains were dissected out, cut midsagittal and the left hemisphere was immersion fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4) overnight after which the hemibrains were cryoprotected in 30% sucrose in 0.1 M phosphate buffer (pH 7.4) for 48 hr.
The brains were frozen and cut in 20 μm thick sagittal sections using a cryostat. Total of six sections per mouse, spanning in 400 μm intervals through the hippocampus, were stained with antibodies against ion- ThT images were converted to binary masks using the thresholding algorithm to allow plaque count and total plaque area to be quantified.
Data are presented as the mean (+SEM) of n = 7-8 individual animals per group.
| Quantitative RT-PCR
After perfusion, cortices of mice were dissected out from the right For the cell culture samples, RNA was extracted using Qiagen RNA-easy kit and 0.5 μg of RNA was transcribed and used for qPCR as described above.
| Ex vivo electrophysiological recording
Acute hippocampal slices were dissected from 36 mice at the age of 3-4 months. From each mouse, 4-6 slices were quickly screened, and the one in the best condition was further recorded. Slices from five animals were excluded due to epileptic activity, four in the Aβ group, one in the Aβ + GW0742 group. The mice were deeply anesthetized with 5% isoflurane (Attane vet ® , Piramal Healthcare UK Limited, Morpeth, United Kingdom), the brains dissected out, and 400 μm thick coronal hippocampal slices prepared using a vibratome ("Pelco101,"
Redding, CA). The slices were maintained at the interface between an oxygen-rich atmosphere and aCSF containing 124 mM NaCl, 3 mM KCl, 1.25 mM KH 2 PO 4 , 2 mM CaCl 2 , 1 mM MgSO 4 , 26 mM NaHCO 3 , and 15 mM D-glucose. Calcium precipitation was prevented by equilibrating the slices with 95% O 2 and 5% CO 2 . The slices were incubated in a chamber containing standard aCSF and DMSO (Sigma-Aldrich, the vehicle solvent for GW0742) for 1 hr before exposing them to one of four treatments for 1 hr 30 min. The treatments included:
(a) 1.0 μM oligomeric Aβ1-42 (American Peptide Company, Sunnyvale, CA, n = 7 mice) for 1 hr, followed by vehicle (10 μM DMSO in aCSF)
for 30 min; (b) vehicle for 1 hr, followed by 10 μM GW0742 for 30 min (n = 9 mice); (c) 1.0 μM Aβ1-42 for 1 hr followed by 10 μM GW0742 (n = 9 mice) for 30 min; and (d) vehicle only for 1 hr 30 min (n = 6 mice). After the treatments, the slices were moved to a recording chamber maintained at 34 AE 1 C with perfusion rate of 0.8 ml/min and equilibrated for 15 min before placing the electrodes and starting the stimulation. We searched for 1-2 mV amplitude of field excitatory postsynaptic potential (fEPSP) at maximum current and stable baseline for 30 min (changes of fEPSP magnitude <10% with mild stimulation current) before application of the stimulation protocol. 
| Electrical stimulation
| Murine neuronal progenitor cell cultures
Neuronal progenitor cells (NPCs) were isolated from the hippocampi of WT C57BL/6JRccHsd mice at embryonic Day 15 (E15) or 18 (E18) and cultured as free-floating neurospheres as described (Gritti et al., 1996; Karkkainen et al., 2014; Reynolds, Tetzlaff, & Weiss, 1992) 
| Statistical analysis
The data were expressed as mean AE SEM and analyzed by SPSS Differences between two groups were analyzed with unpaired twotailed Student's t test. Differences between several groups were analyzed with one-way ANOVA followed by Tukey post hoc test. Differences between the two data sets including two genotypes as well as treatment groups were analyzed with two-way ANOVA followed by
Bonferroni post hoc test.
3 | RESULTS
| AD-patient-derived astrocytes exhibit impaired FA oxidation rescued by PPARβ/δ-agonist, GW0742
To test the hypothesis that FAO contributes to impaired energy metabolism in AD, we examined FAO-related mitochondrial respiration of astrocytes derived from AD-patient (PSEN1ΔE9 astrocytes) and nondemented control subject (control astrocytes) iPSCs (Table 1 ).
All of the used iPSC-astrocytes were previously characterized and have been shown to be functional (Oksanen et al., 2017) . PSEN1ΔE9 cells have also been reported to display an AD-specific phenotype (Oksanen et al., 2017) . When the astrocytes were deprived from exogenous energy substrates for 24 hr, they failed to show significant differences between the genotypes in FAO Seahorse assay measuring mitochondrial parameters, including basal and maximal respiration, proton leak and spare respiratory capacity, and in nonmitochondrial respiration (t(4) = >0.002, p < 1.00, Figure 1a -c). Additional exposure to etomoxir, an inhibitor of CPT1A, allowed the evaluation of the intrinsic capacity of the cells to oxidize endogenous FAs (Blazquez, Sanchez, Daza, Galve-Roperh, & Guzman, 1999) . Indeed, the maximal respiration due to utilization of endogenous FAs was significantly lower in PSEN1ΔE9 astrocytes compared to control astrocytes (t (4) = 3.8, p = .02; Figure 1c ). PSEN1ΔE9 also showed decreased basal FAO, yet the difference failed to reach statistical significance (t (4) = 1.9, p = .13).
Since FA metabolism appears to be strongly influenced by caused an increase in FA utilization (p = .02; Figure 1d ).
| GW0742 enhances the expression of CPT1A, the rate limiting enzyme of FAO
CPT1A is the key enzyme in FA transport across the mitochondrial membrane and controls the rate of mitochondrial β-oxidation of FAs (Jernberg, Bowman, Wolfgang, & Scafidi, 2017) . In the brain, CPT1A is dominantly present in astrocytes and neural progenitor cells. Since we observed etomoxir-induced reduction in FAO and since etomoxir directly blocks the function of CPT1A, we measured the mRNA expression level of CPT1A in GW0742 treated iPSC-astrocytes.
Although there were no significant differences between PSEN1EΔ9
and control astrocytes in basal conditions, both genotypes showed an increase in expression of CPT1A after 24 hr exposure to 1 μM GW0742 (F(1,6) = 1,136, p < .001, two-way ANOVA main treatment effect, Figure 1e ). Further Bonferroni's post hoc test revealed a significantly higher treatment effect in PSEN1EΔ9 astrocytes compared to control astrocytes (p = .01).
| GW0742 does not alter glycolytic metabolism in iPSC-derived astrocytes
To confirm that the observed GW0742-induced increase in OCR in PSEN1EΔ9 astrocytes was indeed because of enhanced FAO, and not caused as a secondary effect of glycolytic metabolism, we performed Seahorse MitoStress assay under high glucose levels. As expected, there was a significant reduction in the basal glycolytic metabolism between the genotypes (F(1, 28) = 1,167, p < .001, two-way ANOVA main genotype effect, Figure 1f ,g), in line with a previous report (Oksanen et al., 2017 ), yet GW0742 failed to alter the basal glycolytic metabolism (glycolysis (F(1, 28) = 0.4, p = .55, two-way ANOVA; Figure 1f ,g). In addition, GW0742 treatment did not alter the OCRvalues of PSEN1ΔE9 astrocytes in the presence of glucose (Supporting Information Figure S1A ), although GW0742 increased nonmitochondrial respiration in both genotypes (Supporting Information Figure S1B ). Since the glycolytic pathway is tightly intertwined with lactate production, we measured L(+)-lactate release from the cell culture supernatant. As previously reported (Oksanen et al., 2017) , lactate secretion was significantly lower in PSEN1ΔE9 astrocytes than in control astrocytes (F(1, 12) = >386.3, p < .001, two-way ANOVA main genotype effect, Figure 1h ). GW0742 failed to alter the lactate release (F(1, 12) = >0.4, p < .55, two-way ANOVA) supporting the hypothesis that PPARβ/δ-agonism affects only FAO.
| GW0742 does not alter iPSC-derived astrocyte cytokine secretion
To evaluate the impact of GW0742 treatment on astrocytic proinflammatory activation, we stimulated iPSC-astrocytes with two key inflammatory cytokines, 50 ng/ml tumor necrosis factor-α (TNFα) in combination with 10 ng/ml interleukin-1β (IL-1β) in the presence or absence of 1 μM GW0742 for 24 hr and measured the levels of secreted cytokines in the cell culture medium. As demonstrated by Oksanen et al. (2017) , PSEN1EΔ9 astrocytes produced higher levels of IL-2, IL-6, IL-10, and GM-CSF (F(1, 16-20) = >13.6, p < .002, twoway ANOVA main genotype effect, Figure 1i ) than control astrocytes.
Administration of GW0742 failed to significantly alter the production of any of the analyzed cytokines, except for IL-10, that was reduced in GW0742 treated PSEN1ΔE9 astrocytes (F(1, 16) = 144, p < .001, two-way; Figure 1i ).
| APP/PS1 astrocytes show impaired FAO
To evaluate whether astrocytes in APP/PS1 TG mice show similar impairment in FAO, we isolated and cultured astrocytes from APP/PS1 mice and their WT controls for seahorse FAO assay. In line with the data obtained from PSEN1ΔE9 iPSC-astrocytes, astrocytes from APP/PS1 mice showed significantly reduced maximal endogenous FAO compared to astrocytes cultured from WT mice (Supporting Information Figure S1C -E). Treatment with GW0742 (f, g) n = 7-9 technical replicates. (h) Lactate release was measured from media with an enzymatic assay and the data were normalized to protein content. n = 4 technical replicates repeated with two biological replicates. (i) Concentrations of IL-2, IL-6, IL-10, GM-CSF, and MCP-1 were quantified from media after stimulation with TNFα (50 ng/ml) and IL-1β (10 ng/ml) for 24 hr using CBA assay shown as fold change to vehicle treated control astrocytes. n = 4-6 technical replicates. All data are presented as mean AE SEM with *p < .05, *p < .01, ***p < .001 as analyzed by unpaired t test or two-way ANOVA followed by Bonferroni post hoc test. FCCP = carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; veh = vehicle containing DMSO the same v/v% as GW0742; GW42 = 1 μM GW0742 for 24 hr;, CTRL = control astrocyte; PSEN1ΔE9 = PSEN1ΔE9 astrocyte; CPT1A = carnitine palmitoyltransferase 1A; GM-CSF = granulocyte-macrophage colony-stimulating factor; MCP-1 = monocyte chemoattractant protein-1 induced a trend toward increase in FAO in TG astrocytes (Supporting Information Figure S1E ).
| GW0742 ameliorates memory deficits in APP/PS1 mice and increases Cpt1a expression
To test whether GW0742 is capable of ameliorating AD-related memory impairment, 12-month-old APP/PS1 mice were orally administered with 30 mg/kg GW0742 for 14 days after which the mice underwent a contextual fear conditioning test (Figure 2a ). In line with previous studies (Kilgore et al., 2010) , vehicle treated APP/PS1 mice exhibited a significant reduction in conditional freezing compared to WT mice (t(38) = 3.3, p = .002, unpaired t test, Figure 2b ). Moreover, this short treatment period with GW0742 was capable of reversing the deficits in contextual memory (t(16) = 2.4, p = .03, unpaired t test, Figure 2b ).
To further test the effect of GW0742 treatment on locomotor activity of the mice, we performed an OF test before the treatment onset to evaluate basal activity levels, as well as after the treatment period, to determine the treatment effect ( Figure 2c ). We failed to observe genotype-specific differences on the basal activity level measured as mean velocity of movement (F(1,14) = 0.1, p = .79, two-way ANOVA main genotype effect,), yet the GW0742 treated APP/PS1 mice showed increased activity compared to other groups, resulting in significant genotype × treatment interaction (F(1, 24) = 12.7, p = .003, two-way ANOVA, Bonferroni's post hoc test p = .002; Figure 2c ). Since increased behavioral activity could lead to reduced body weight, we determined the change in body weight before and after the treatment.
There were no significant changes in body weight, although there was a trend of weight reduction in APP/PS1 -mice treated with GW0742 compared to TG vehicle group (F(1, 29) = >0.7, p < .42, two-way ANOVA, Figure 2d ). To confirm that the amelioration in memory was indeed related to mechanisms underlying FAO, we measured the relative cortical expression levels of Cpt1a and Cpt2 of the treated APP/PS1. Similar to the human iPSC-astrocytes, we found no genotype difference in the mRNA expression levels of Cpt1a (Figure 2e ). However, GW0742 treated mice showed increased levels of Cpt1a in both genotypes, yet the increase reached statistical significance only in APP/PS1 cortices (F(1, 28) = 10.9, p = .003, two-way ANOVA main treatment effect, Bonferroni's post hoc for APP/PS1 vehicle × APP/PS1 GW0742, p = .03, Figure 2e ). The levels of Cpt2 were not altered between the groups (F (1, 28)= > 0.7, p < .39, two-way ANOVA, Figure 2f ), suggesting that PPARβ/δ-agonism affects only the rate-limiting Cpt1a.
3.7 | PPARβ/δ-agonism by GW0742 fails to alter AD-like pathological hallmarks in vivo
Next we assessed whether the beneficial behavioral outcome of GW0742 treatment was related to effects on AD-related pathological hallmarks. Quantification of the hippocampal ionized calcium binding adaptor molecule 1 (IBA1) and GFAP immunoreactivities revealed that the levels of both markers were unaltered by GW0742 treatment (Supporting Information Figure S3A, B) . Further, we evaluated the effect of GW0742 treatment on Aβ levels by ELISA (Supporting Information Figure S2 ), immunohistochemistry using 6E10-antibody (Supporting Information Figure S3C ), and by ThT staining (Supporting Information Figure S3D ). GW0742 treatment did not alter any of these parameters (Supporting Information Figures S3C, D; S2 ).
| Inflammation related gene expression is altered by GW0742 treatment
APP/PS1 mice showed a relatively mild phenotype in the expression of cortical inflammatory genes, with approximately twofold upregulation in the expression levels of Il1b, Tnfα, Ccl2 (C-C motif chemokine 2, also referred as MCP1), Cxcr2 (C-X-C chemokine receptor type 2), and Tlr4 (toll-like receptor 4), while the expression levels of Respective gene expression levels of Cpt2. n = 8. All data are presented as mean AE SEM with *p < .05 and **p < .01 as analyzed by t test or two-way ANOVA followed by Bonferroni post hoc test. cpt1a = carnitine palmitoyltransferase 1a
Il6, C1qa (complement C1q subcomponent subunit A), and Socs1 (suppressor of cytokine signaling 1) were not different between the genotypes (Supporting Information Figure S3E ). GW0742 treated APP/PS1 mice showed reduced levels of Ccl2, C1qa, and Socs1. In WT mice, GW0742 similarly reduced Ccl2, but additionally also Il1b and Tnfα.
3.9 | GW0742 attenuates Aβ-induced suppression of LTP ex vivo
To elucidate the impact of Aβ and GW0742 on synaptic plasticity, we investigated whether GW0742 attenuates Aβ-induced impairment in LTP in ex vivo hippocampal slices. LTP was induced in the CA3-CA1
pathway of the hippocampus using TBS (Figure 3a) . The field excitatory post-synaptic potential (fEPSP) amplitudes after TBS stimulation were normalized to pre-TBS baseline. There was a significant treatment effect (Figure 3b The quantitative analysis of LTP 60 min after HFS. All data are presented as mean AE SEM with **p < .01. (veh n = 6, GW42 n = 10, Aβ n = 7, Aβ GW42 n = 10) mice. Although impairment in FAO is unlikely to be the cause for ADrelated pathology, our study suggests that FAO may be therapeutically targeted.
AD pathology is known to impair brain energy metabolism. Glucose hypometabolism has been suggested to be an early sign of AD even prior to the appearance of Aβ deposition (Chen & Zhong, 2013; Mosconi, Pupi, & De Leon, 2008; Nashold Jr. & Goldner, 1975) . Exposure of astrocytes to Aβ and proinflammatory cytokines has been shown to increase astrocytic glycolysis without enhancing lactate production (Allaman et al., 2010; Gavillet, Allaman, & Magistretti, 2008) , suggesting impairment in astrocytic metabolic activity. Given the dependency of neurons on astrocytic energy supply, it is not surprising that this influences neuronal functions (Allaman et al., 2010) .
Indeed, astrocytic production of lactate is required for the hippocampal memory formation and LTP (Suzuki et al., 2011) . Importantly, lactate production is impaired in the PSEN1EΔ9 iPSC-astrocytes used in this study (Oksanen et al., 2017) , implying that an AD-causing genotype directly impairs astrocytic energy metabolism. Although FAs are oxidized in healthy astrocytes, they become an even more important source of energy when brain health and normal glycolysis are compromised. Glucose deprivation induces FAO in astrocytes in hypoxic/ischemic conditions and may serve as an attempt to cope with the injury (Cabodevilla et al., 2013) . For example, ischemia has been reported to induce fatty acid binding protein 3 expression in astrocytes in adult monkeys subjected to ischemic injury 15 days post injury (Boneva et al., 2011) . Impairment in FAO is also evident in AD, indicated as reduced levels of the FAO metabolites, acylcarnitines, and ketones in the plasma of AD patients (Ciavardelli et al., 2016) .
Moreover, octanoate, a substrate for FAO has been shown to counteract the Aβ-induced memory deficits in chicks (Gibbs et al., 2009 further increase the production of Aβ1-42 (Grimm et al., 2005) . Ceramides are converted to sphingosines, which feed as substrates for FA oxidation. Although PPARβ/δ has not been shown to drive the function of ceramidase, it does participate into catabolism of ceramides by activating other enzymes taking part in this process (Aleshin & Reiser, 2014 (Das, Gangwal, Damre, Sangamwar, & Sharma, 2014) . In accordance, inhibition of PPARβ/δ impairs hippocampal dependent cognitive functions (Benedetti et al., 2016) .
These studies are well in line with our study showing that administration of GW0742 to APP/PS1 mice reversed the contextual fear conditioning deficit and increased hippocampal neurogenesis, the latter of which we previously demonstrated to be reduced in the hippocampi of APP/PS1 mice (Puli et al., 2012; Taniuchi et al., 2007) . To prove further the ability of PPARβ/δ to enhance neurogenesis, we used a mouse NPC model of neurogenesis and showed that GW0742 induces the production of Tuj-1 positive neurons. Since there was no genotype difference in differentiation of embryonic NPCs between WT and APP/PS1 as previously published (Karkkainen, Magga, Koistinaho, & Malm, 2012) , the effect of GW0742 was only studied in WT NPCs. Benedetti et al. reported a similar finding in cortical neurons in which maturation was induced by administration of GW0742 (Benedetti et al., 2016) . In addition, it has been shown that PPARβ/δ promotes the differentiation of other brain cell types, such as oligodendrocytes (D'Angelo et al., 2011) . Neurogenesis and neuronal differentiation are driven by multiple factors. Yet neuronal stem cells in the subventricular zone of adult animals have been shown to rely on FAO for energy production and FAs, in particular, support their neurogenic activity (Stoll et al., 2015) . This is in line with our study showing that GW0742 induced neurogenesis is FAO dependent.
Astrocytes and NPCs are the main cell types in the brain that utilize FAO for their energy expenditure (Edmond, Robbins, Bergstrom, Cole, & de Vellis, 1987; Knobloch et al., 2017) and FAs have been shown to be produced endogenously in neuronal stem cells (Knobloch et al., 2013) . This prompted us to focus this study on astrocytes and
NPCs. The produced FAs can be utilized as a source of energy, which is vital especially when the brain encounters neurodegeneration and compromised neuronal functions. Upon induction of FAO, FAs are esterified to acyl-CoA by acyl-CoA synthase and enter the mitochondria. In the intermembrane space of mitochondria, the fatty acyl-CoA is converted to a fatty acylcarnitine by CPT1 and subsequently transported across the mitochondrial inner membrane space. An increase in the expression level of CPT1a, the main isoform of CPT1 expressed in astrocytes, is indicative of increased FAO since it is the rate-limiting transport enzyme of FAs (Blazquez et al., 1999; Jernberg et al., 2017) .
Etomoxir, which blocks the activity of CPT1, is widely used to inhibit β-oxidation. Indeed, in the current study etomoxir blocked the astrocytic FAO and resulted in loss of GW0742-induced differentiation of NPCs.
Although we failed to observe an anti-inflammatory effect of GW0742 in iPSC-astrocytes, others have reported that PPARβ/δ activation alleviates astrocytic pro-inflammatory activation (Chistyakov, Aleshin, Astakhova, Sergeeva, & Reiser, 2015) . In contrast, the impact of GW0742 on suppression of inflammation may be model dependent, as Schnegg et al. reported that GW0742 inhibited neuroinflammation, yet failed to restore neurogenesis or prevent hippocampal dependent cognitive deficits (Schnegg et al., 2013) . Similarly, we have previously shown that GW0742 administration to 5xFAD mice suppresses microglial activation and prompts the clearance of Aβ deposits (Malm, Mariani, Donovan, Neilson, & Landreth, 2015) , whereas in the current study, when administered to APP/PS1 mice, we failed to observe changes in microgliosis. The pathology progression of 5xFAD mice is aggressive leading to severe brain amyloidosis already at the age of 4 months whereas at the same age the APP/PS1 mice are only starting to build up plaques (Jankowsky et al., 2004; Oakley et al., 2006) . The same applies for the brain inflammatory profile: the levels of pro-inflammatory cytokines are higher in 5xFAD mice compared to APP/PS1. Similarly, mouse model dependent alterations are also possible in astrocytic FA oxidation.
Taken together, this study shows for the first time that human iPSC-derived astrocytes carrying AD mutation PSEN1ΔE9 exhibit impaired FAO. This deficit is rescued by activation of PPARβ/δ with a synthetic agonist, GW0742. A similar deficit in FAO is also observed in astrocytes isolated from adult APP/PS1 mice. Treatment of APP/PS1 mice with GW0742 improves cognitive deficits of the mice.
This study is the first to address the AD related defect in FA oxidation specifically in astrocytes and suggests that astrocytic lipid metabolism provides a potential target for AD therapy.
